Journal
CLINICAL INFECTIOUS DISEASES
Volume 53, Issue -, Pages S33-S55Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir475
Keywords
-
Categories
Funding
- Consensus Medical Communication
- Astellas
- Sanofi Pasteur
- Astrazeneca
- Therafan
- Forest Laboratories and Novartis
- TRIUS
- Covidien
- BARD
- National Heart, Lung, and Blood Institute [K23HL096054]
- University of Colorado School of Medicine
- Consensus Medical Communications
- Ortho-McNeil Janssen Scientific Affairs, LLC.
- Merck
- Cubist
- Pfizer
- Johnson Johnson
- National Heart, Lung, and Blood Institute
- GlaxoSmithKline
Ask authors/readers for more resources
The emerging problem of antibiotic resistance, especially among Gram-negative bacteria (GNB), has become a serious threat to global public health. Very few new antibacterial classes with activity against antibiotic-resistant GNB have been brought to market. Renewed and growing attention to the development of novel compounds targeting antibiotic-resistant GNB, as well as a better understanding of strategies aimed at preventing the spread of resistant bacterial strains and preserving the efficacy of existing antibiotic agents, has occurred. The Gram-Negative Resistance Summit convened national opinion leaders for the purpose of analyzing current literature, epidemiologic trends, clinical trial data, therapeutic options, and treatment guidelines related to the management of antibiotic-resistant GNB infections. After an in-depth analysis, the Summit investigators were surveyed with regard to 4 clinical practice statements. The results then were compared with the same survey completed by 138 infectious disease and critical care physicians and are the basis of this article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available